Back to Peptide Index

BAM15

MitochondriaEvidence Level: researchNot FDA-approved for general therapeutic use; ongoing research and preclinical studies.
Peptide #22

BAM15 is a mitochondrial uncoupling agent that selectively dissipates the mitochondrial proton gradient, significantly increasing cellular energy expenditure. Unlike traditional mitochondrial uncouplers, BAM15 demonstrates higher specificity and safety, making it a promising candidate for metabolic regulation and obesity treatment.

Overview

BAM15 is an innovative mitochondrial uncoupling agent recognized for its ability to enhance metabolic function, facilitate fat loss, and potentially combat obesity and metabolic disorders.

How It Works

BAM15 selectively increases mitochondrial proton leak without significantly affecting mitochondrial membrane potential or causing excessive production of reactive oxygen species (ROS).

Clinical Effects

Enhances metabolic function, facilitates fat loss, improves insulin sensitivity, glucose metabolism, and energy utilization, reduces fat storage, enhances overall metabolic efficiency, potential benefits in cardiovascular function and reduced systemic inflammation.

Therapeutic Applications

Obesity treatment, metabolic disorders, metabolic syndrome, type 2 diabetes, cardiovascular health, mitochondrial health.

Research Studies

Clinical Trials

Human clinical trials are limited, with ongoing research aimed at validating preliminary positive outcomes in obesity management, metabolic enhancement, and cardiovascular health.

Preclinical Studies

Preclinical studies consistently demonstrate significant decreases in adiposity, improved metabolic health, and enhanced energy expenditure.

Frequently Asked Questions

Is BAM15 legally available? BAM15 is legally available for research purposes through specialized suppliers but is not yet FDA-approved for general therapeutic use. Have human trials been conducted with BAM15? Human clinical trials are limited, with ongoing research aimed at validating preliminary positive outcomes in obesity management, metabolic enhancement, and cardiovascular health. What are potential side effects of BAM15? Reported side effects from early research are minimal, typically mild and transient. Long-term safety profiles remain under ongoing investigation. How is BAM15 typically administered? BAM15 is typically administered orally or through subcutaneous injections in research settings, with dosage protocols tailored according to specific therapeutic objectives and clinical research protocols. Can BAM15 be combined with other metabolic treatments? Controlled clinical studies are required to safely evaluate the effectiveness and interactions of BAM15 when combined with other therapeutic interventions. Does BAM15 offer permanent metabolic benefits? BAM15 significantly enhances metabolic function and promotes sustained fat reduction during administration. Long-term sustained benefits typically require ongoing treatment supported by comprehensive lifestyle management.

Quick Information

Safety Information

Safety Profile

Long-term safety profiles remain under ongoing investigation.

Contraindications

Side Effects: Reported side effects from early research are minimal, typically mild and transient. Safety Profile: Long-term safety profiles remain under ongoing investigation.

Side Effects

Reported side effects from early research are minimal, typically mild and transient.

Research References

Alexopoulos, S. J., et al. (2020). Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications. Axelrod, C. L., et al. (2021). BAM15-mediated mitochondrial uncoupling protects against obesity and improves metabolic health. Cell Metabolism. McIlwain, D. R., et al. (2022). Therapeutic targeting of mitochondrial uncoupling proteins in metabolic disease. Biochimica et Biophysica Acta (BBA)-Bioenergetics.

Additional Resources

View Source